Last 29 quarters of trend data · Healthcare · Oncology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.27 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.13 | 0.70 | 3.08 | 1.74 | 0.16 | 0.74 | 0.47 | 0.33 | 0.41 | 0.66 | 0.55 | 0.74 | 0.60 | 0.52 | 1.52 | 1.02 | 0.48 | 0.66 | 0.51 | 0.55 | 0.65 |
| — | -5.1% | +556.7% | +424.6% | -61.7% | +11.4% | -14.0% | -55.4% | -31.3% | +27.4% | -64.1% | -26.7% | +26.5% | -21.2% | +195.9% | +85.0% | -26.9% | -5.3% | -43.1% | -45.5% | -65.8% | |
| P/FCF | — | — | — | — | 16.85 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -164.7% | -6.3% | -6.1% | -7.4% | -162.5% | -38.5% | -31.3% | -18.9% | -38.1% | -17.4% | -22.6% | -18.1% | -18.6% | -20.1% | -22.9% | -23.2% | -20.9% | -17.4% | -18.1% | -15.5% | -10.9% |
| — | +83.6% | +80.6% | +60.8% | -326.8% | -120.7% | -38.3% | -4.3% | -105.0% | +13.1% | +1.0% | +21.9% | +11.2% | -15.3% | -26.1% | -49.6% | -92.6% | -85.8% | -116.5% | -84.7% | -19.5% | |
| ROA | -151.1% | -5.9% | -5.8% | -7.0% | -148.0% | -25.7% | -23.7% | -15.6% | -33.3% | -15.3% | -19.6% | -15.5% | -14.7% | -14.9% | -17.4% | -18.9% | -18.1% | -15.7% | -16.7% | -14.7% | -10.4% |
| — | +76.8% | +75.6% | +55.2% | -344.7% | -67.4% | -21.0% | -0.6% | -126.9% | -2.5% | -12.3% | +17.8% | +19.1% | +4.8% | -4.0% | -28.7% | -74.5% | -74.8% | -107.8% | -81.3% | -21.1% | |
| ROIC | — | -45.0% | — | — | — | -367.0% | -192.9% | -109.1% | -134.5% | -275.3% | -430.5% | -47.0% | -38.7% | -35.6% | -35.4% | -36.3% | -27.0% | -20.2% | -22.8% | -22.7% | -16.8% |
| — | +87.7% | — | — | — | -33.3% | +55.2% | -132.4% | -248.0% | -672.8% | -1117.0% | -29.3% | -43.0% | -76.3% | -54.9% | -60.3% | -60.5% | -44.0% | -90.0% | +8.5% | +92.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.21 | 0.15 | 0.12 | 0.10 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| — | -99.0% | — | -97.7% | -99.7% | +13763.4% | +4413.4% | +2008.3% | +1185.7% | -87.7% | -77.2% | -59.6% | -40.8% | +5.2% | +112.3% | +90.2% | +80.2% | +62.9% | -12.3% | +14.0% | +30.7% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 12.98 | 14.80 | 19.73 | 22.48 | 12.98 | 3.73 | 4.39 | 8.64 | 14.07 | 8.68 | 6.79 | 7.07 | 6.31 | 3.75 | 3.72 | 4.06 | 5.75 | 8.04 | 10.98 | 13.45 | 24.23 |
| — | +296.8% | +349.2% | +160.3% | -7.7% | -57.0% | -35.3% | +22.1% | +123.0% | +131.5% | +82.6% | +74.1% | +9.6% | -53.4% | -66.1% | -69.8% | -76.3% | -56.9% | -51.5% | -36.3% | -20.3% | |
| Quick Ratio | 12.98 | 14.80 | 19.73 | 22.48 | 12.98 | 3.73 | 4.39 | 8.64 | 14.07 | 8.68 | 6.79 | 7.07 | 6.31 | 3.75 | 3.72 | 4.06 | 5.75 | 8.04 | 10.98 | 13.45 | 24.23 |
| — | +296.8% | +349.2% | +160.3% | -7.7% | -57.0% | -35.3% | +22.1% | +123.0% | +131.5% | +82.6% | +74.1% | +9.6% | -53.4% | -66.1% | -69.8% | -76.3% | -56.9% | -51.5% | -36.3% | -20.3% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 29 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying DMRA stock.
Damora Therapeutics, Inc.'s current P/E is -1.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Damora Therapeutics, Inc.'s business trajectory between earnings reports.